![Charles Akle](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Charles Akle
Directeur/Bestuurslid bij Masonic Charitable Foundation
Profiel
Charles Akle is the founder of Immodulon Therapeutics Ltd., which was founded in 2007.
Currently, he holds a position as a Trustee at Masonic Charitable Foundation.
Actieve functies van Charles Akle
Bedrijven | Functie | Begin |
---|---|---|
Masonic Charitable Foundation
![]() Masonic Charitable Foundation Miscellaneous Commercial ServicesCommercial Services The Masonic Charitable Foundation is a charity organization that provides support to Freemasons in and around the UK. The non-profit company is based in London, UK, and has subsidiaries in the United Kingdom. The organization offers various services and assistance to its members. Les Hutchinson has been the CEO of the British company since 2016. | Directeur/Bestuurslid | - |
Eerdere bekende functies van Charles Akle
Bedrijven | Functie | Einde |
---|---|---|
Immodulon Therapeutics Ltd.
![]() Immodulon Therapeutics Ltd. BiotechnologyHealth Technology Part of Lifexx SA, Immodulon Therapeutics Ltd. is a late-stage clinical biotechnology company based in Uxbridge, UK. Immodulon is developing a highly differentiated cancer immunotherapy approach that primes the patient’s own innate immune system with the aim to significantly enhance the efficacy of a broad range of anti-cancer therapies, including chemotherapy and checkpoint inhibitors. The British company is developing imm-101, a heat-killed mycobacterium obuense, as a broad-spectrum immunomodulatory agent with the potential to treat a range of difficult-to-treat tumors including those considered to be immunologically “ cold, ” such as pancreatic cancer. Immodulon's imm-101 based immunotherapy complements other cancer therapies, including immune checkpoint inhibitors and chemotherapy. The company is focused on developing safe and effective immunotherapy treatments. The company was founded in 2007 by Charles Akle, John L. Stanford. Gertjan Bartlema has been the CEO of the company since 2022. | Oprichter | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 2 |
---|---|
Masonic Charitable Foundation
![]() Masonic Charitable Foundation Miscellaneous Commercial ServicesCommercial Services The Masonic Charitable Foundation is a charity organization that provides support to Freemasons in and around the UK. The non-profit company is based in London, UK, and has subsidiaries in the United Kingdom. The organization offers various services and assistance to its members. Les Hutchinson has been the CEO of the British company since 2016. | Commercial Services |
Immodulon Therapeutics Ltd.
![]() Immodulon Therapeutics Ltd. BiotechnologyHealth Technology Part of Lifexx SA, Immodulon Therapeutics Ltd. is a late-stage clinical biotechnology company based in Uxbridge, UK. Immodulon is developing a highly differentiated cancer immunotherapy approach that primes the patient’s own innate immune system with the aim to significantly enhance the efficacy of a broad range of anti-cancer therapies, including chemotherapy and checkpoint inhibitors. The British company is developing imm-101, a heat-killed mycobacterium obuense, as a broad-spectrum immunomodulatory agent with the potential to treat a range of difficult-to-treat tumors including those considered to be immunologically “ cold, ” such as pancreatic cancer. Immodulon's imm-101 based immunotherapy complements other cancer therapies, including immune checkpoint inhibitors and chemotherapy. The company is focused on developing safe and effective immunotherapy treatments. The company was founded in 2007 by Charles Akle, John L. Stanford. Gertjan Bartlema has been the CEO of the company since 2022. | Health Technology |